Shares of MyoKardia are soaring about 60% in Monday’s pre-market trading after the biopharma company agreed to be acquired by Bristol Myers Squibb …
It is a nice time to be a Myokardia Inc (NASDAQ:MYOK) investor, particularly on back of the biotech firm’s successful Phase 2a PIONEER …
Upon releasing positive data for lead drug candidate Mavacamten on Monday, investors flocked to Myokardia Inc (NASDAQ:MYOK), sending the stock soaring by 83%. …
Healthcare analysts expressed their opinions on Myokardia Inc (NASDAQ:MYOK) and Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) after the former released promising clinical data in symptomatic, obstructive hypertrophic …
Written by Dan Cohen and Scott Matusow Currently, we are in the midst of a dramatic shift in the field of biotechnology and …
